Integral Health Asset Management LLC Grows Position in Roivant Sciences Ltd. $ROIV

Integral Health Asset Management LLC grew its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 25.0% during the 3rd quarter, Holdings Channel.com reports. The firm owned 750,000 shares of the company’s stock after acquiring an additional 150,000 shares during the period. Integral Health Asset Management LLC’s holdings in Roivant Sciences were worth $11,348,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Marshall Wace LLP boosted its stake in shares of Roivant Sciences by 316.5% during the 3rd quarter. Marshall Wace LLP now owns 3,978,001 shares of the company’s stock worth $60,187,000 after acquiring an additional 3,022,851 shares in the last quarter. Kennedy Capital Management LLC boosted its position in Roivant Sciences by 96.7% during the third quarter. Kennedy Capital Management LLC now owns 109,571 shares of the company’s stock worth $1,658,000 after purchasing an additional 53,869 shares in the last quarter. Invesco Ltd. boosted its position in Roivant Sciences by 5.1% during the third quarter. Invesco Ltd. now owns 1,769,358 shares of the company’s stock worth $26,770,000 after purchasing an additional 85,259 shares in the last quarter. BNP Paribas Financial Markets grew its stake in Roivant Sciences by 1,025.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,759,880 shares of the company’s stock valued at $26,627,000 after acquiring an additional 1,603,535 shares during the last quarter. Finally, WINTON GROUP Ltd raised its position in Roivant Sciences by 161.1% during the third quarter. WINTON GROUP Ltd now owns 543,333 shares of the company’s stock worth $8,221,000 after acquiring an additional 335,269 shares during the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, insider Frank Torti sold 1,400,000 shares of the firm’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $27.42, for a total transaction of $38,388,000.00. Following the completion of the transaction, the insider directly owned 13,736,547 shares of the company’s stock, valued at $376,656,118.74. This trade represents a 9.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Matthew Gline sold 1,740,000 shares of Roivant Sciences stock in a transaction on Monday, December 15th. The stock was sold at an average price of $21.68, for a total transaction of $37,723,200.00. Following the completion of the transaction, the chief executive officer directly owned 17,290,820 shares of the company’s stock, valued at approximately $374,864,977.60. This represents a 9.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 10,368,014 shares of company stock worth $251,414,748 over the last 90 days. Company insiders own 10.80% of the company’s stock.

Roivant Sciences Price Performance

NASDAQ:ROIV opened at $28.06 on Friday. Roivant Sciences Ltd. has a 1-year low of $8.73 and a 1-year high of $30.33. The firm has a 50-day moving average of $25.29 and a two-hundred day moving average of $20.63. The stock has a market cap of $20.08 billion, a P/E ratio of -23.98 and a beta of 1.17.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ROIV. The Goldman Sachs Group increased their target price on Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a report on Monday, December 15th. HC Wainwright lifted their price target on shares of Roivant Sciences from $33.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Citigroup boosted their price objective on shares of Roivant Sciences from $26.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, February 10th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. Finally, Wall Street Zen raised shares of Roivant Sciences from a “strong sell” rating to a “hold” rating in a research report on Sunday, November 16th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Roivant Sciences currently has an average rating of “Moderate Buy” and an average price target of $28.81.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.